159 related articles for article (PubMed ID: 17192735)
1. Impact of self-perceived bothersomeness on health-related quality of life in women with overactive bladder symptoms.
Oh SJ; Ku JH
Urol Int; 2007; 78(1):63-9. PubMed ID: 17192735
[TBL] [Abstract][Full Text] [Related]
2. Does condition-specific quality of life correlate with generic health-related quality of life and objective incontinence severity in women with stress urinary incontinence?
Oh SJ; Ku JH
Neurourol Urodyn; 2006; 25(4):324-9; discussion 330. PubMed ID: 16534817
[TBL] [Abstract][Full Text] [Related]
3. Impact of fesoterodine on quality of life: pooled data from two randomized trials.
Kelleher CJ; Tubaro A; Wang JT; Kopp Z
BJU Int; 2008 Jul; 102(1):56-61. PubMed ID: 18564231
[TBL] [Abstract][Full Text] [Related]
4. Comparison of three disease-specific quality-of-life questionnaires (Bristol Female Lower Urinary Tract Symptoms, Incontinence Quality of Life and King's Health Questionnaire) in women with stress urinary incontinence.
Oh SJ; Ku JH
Scand J Urol Nephrol; 2007; 41(1):66-71. PubMed ID: 17366105
[TBL] [Abstract][Full Text] [Related]
5. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of health-related quality of life outcomes with darifenacin.
Abrams P; Kelleher C; Huels J; Quebe-Fehling E; Omar MA; Steel M
BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056
[TBL] [Abstract][Full Text] [Related]
7. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.
Coyne KS; Sexton CC; Irwin DE; Kopp ZS; Kelleher CJ; Milsom I
BJU Int; 2008 Jun; 101(11):1388-95. PubMed ID: 18454794
[TBL] [Abstract][Full Text] [Related]
8. Impact of stress urinary incontinence and overactive bladder on quality of life in Thai women attending the urogynecology clinic.
Wattanayingcharoenchai R; Manonai J; Vannatim N; Saritapirak S; Imsomboon C; Chittacharoen A
J Med Assoc Thai; 2007 Jan; 90(1):26-31. PubMed ID: 17621729
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life and sexual function in women with stress urinary incontinence and overactive bladder.
Oh SJ; Ku JH; Choo MS; Yun JM; Kim DY; Park WH
Int J Urol; 2008 Jan; 15(1):62-7; discussion 67. PubMed ID: 18184175
[TBL] [Abstract][Full Text] [Related]
10. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin.
Kelleher CJ; Cardozo L; Chapple CR; Haab F; Ridder AM
BJU Int; 2005 Jan; 95(1):81-5. PubMed ID: 15638900
[TBL] [Abstract][Full Text] [Related]
11. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
12. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment.
Awa Y; Suzuki H; Hamano S; Okano T; Sakurayama Y; Ohki T; Egoshi K; Ota S; Mori I; Ichikawa T
Int J Urol; 2008 Aug; 15(8):709-15. PubMed ID: 18662175
[TBL] [Abstract][Full Text] [Related]
13. Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies.
Kelleher CJ; Dmochowski RR; Berriman S; Kopp ZS; Carlsson M
BJU Int; 2012 Aug; 110(3):392-400. PubMed ID: 22129365
[TBL] [Abstract][Full Text] [Related]
14. Validation of a patient-administered questionnaire to measure the severity and bothersomeness of lower urinary tract symptoms in uncomplicated urinary tract infection (UTI): the UTI Symptom Assessment questionnaire.
Clayson D; Wild D; Doll H; Keating K; Gondek K
BJU Int; 2005 Aug; 96(3):350-9. PubMed ID: 16042729
[TBL] [Abstract][Full Text] [Related]
15. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
16. Electromotive drug-administration: a pilot study for minimal-invasive treatment of therapy-resistant idiopathic detrusor overactivity.
Bach P; Wormland RT; Möhring C; Goepel M
Neurourol Urodyn; 2009; 28(3):209-13. PubMed ID: 19205067
[TBL] [Abstract][Full Text] [Related]
17. Redefining response in overactive bladder syndrome.
Payne CK; Kelleher C
BJU Int; 2007 Jan; 99(1):101-6. PubMed ID: 17227496
[TBL] [Abstract][Full Text] [Related]
18. What is the effect of overactive bladder symptoms on woman's quality of life during and after first pregnancy?
Van Brummen HJ; Bruinse HW; Van de Pol G; Heintz AP; Van der Vaart CH
BJU Int; 2006 Feb; 97(2):296-300. PubMed ID: 16430633
[TBL] [Abstract][Full Text] [Related]
19. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder.
Coyne KS; Matza LS; Kopp Z; Abrams P
Eur Urol; 2006 Jun; 49(6):1079-86. PubMed ID: 16460875
[TBL] [Abstract][Full Text] [Related]
20. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
